Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at email@example.com
Huntington Therapy Valbenazine Demonstrates Significant, Long-Term Benefits in KINECT-HD Open-Label Extension
Similar to the double-blind study, valbenazine was well-tolerated with clinically meaningful improvement in chorea severity after nearly a year of treatment.
Multicentric Studies Assessing Effective Nonpharmacological Rehab Techniques in Multiple Sclerosis Ataxia Needed
Most of the studies included highlighted the increasing level of difficulty in all exercises performed and that the transition from one kinematic protocol to the other depended on the patient’s rate of improvement.
IL-6 Inhibitor Tocilizumab Effective in Treating NMOSD, Meta-Analysis Suggests
A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.
NeuroVoices: Susan Landau, PhD, on the POINTER Trial and Understanding the Link Between Elevated Alzheimer Biomarkers and Cognition
The research neuroscientist at the University of California Berkeley provided insight on findings from the US POINTER study and why previous thoughts on the link between relevant biomarkers and cognition may be slightly incorrect.
Elecsys Neurofilament Light Test Gains Breakthrough Device Designation as Way to Track MS Disease Activity
Neurofilament light, a marker of neuroaxonal damage, is correlated with increased levels of disease progression and clinical relapses.
Patient Dosing Commenced in Phase 2 ASCEND Study of Parkinson Agent CVN424
The trial will feature 60 individuals with early-stage Parkinson disease who will be randomly assigned 1:1 to either daily CVN424 or placebo for a 12-week treatment period.
FDA Clears Phase 2 Study of CAR T-Cell Therapy KYV-101 in Myasthenia Gravis
In addition to myasthenia gravis, KYV-101 is being explored in other disorders like systemic sclerosis, multiple sclerosis, and lupus nephritis.
Carbidopa Levodopa Enteral Suspension Leads to Greater Cost-Effectiveness Over Standard Care
Carbidopa levodopa enteral suspension for Parkinson disease demonstrated cost-effectiveness compared to standard care, with an incremental cost-effectiveness ratio of $7711/QALY in a real-world study.
Nicotinamide Riboside Supplementation Improves Neuromotor Function in Ataxia Telangiectasia
Long-term nicotinamide riboside use in patients with ataxia telangiectasia showed safety, improved motor coordination, and eye movements, suggesting potential disease attenuation.
Assessing the Therapeutic Potential of AOC 1001 in Myotonic Dystrophy Type 1
Steve Hughes, MD, chief medical officer at Avidity, provided perspective on recently announced positive phase 1/2 and OLE data evaluating AOC 1001, an investigational antisense oligonucleotide, in patients with myotonic dystrophy type 1.
Cognitive Benefits in Multiple Sclerosis Seen Through Transcranial Current Stimulation
Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.
ATA188 Fails to Meet Primary End Point In Phase 2 EMBOLD Study of Progressive MS
The phase 2 EMBOLD study on ATA188, an allogenic T-cell immunotherapy for non-active progressive multiple sclerosis, did not meet its primary endpoint of confirmed disability improvement after 12 months of treatment.
Study Fails to Identify Correlations Between Cardiac Issues and Lamotrigine
A retrospective study on veterans using lamotrigine found no clear association between the drug and cardiac conduction abnormalities, prompting the need for further research.
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Nerivio Neuromodulation Therapy Demonstrates Continued Efficacy, Safety At 1 Year
Over a year’s worth of treatment, investigators observed consistent and persistent efficacy in pain relief, pain freedom, functional disability relief, and functional disability freedom.
NeuroVoices: Joseph Foss, MD, on NTRX-07 and CBR2-Targeting Therapies for Alzheimer Disease
The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.
Special Episode: FDA Green-Lights Vamorolone for Duchenne Muscular Dystrophy
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Barry J. Byrne, MD, PhD. [LISTEN TIME: 10 minutes]
Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings
Preliminary data from a phase 1 study suggest that ALKS 2680, an investigational orexin 2 receptor agonist, is safe and improves sleep latency in narcolepsy patients, leading to plans for a phase 2 study.
FDA Clears Neurovalens’ Modius Sleep Device for Insomnia
Modius Sleep is designed to send a safe electrical pulse into the vestibular nerve, influencing the areas of the hypothalamus and brain stem that control circadian rhythm and sleep patterns.
CSA Spinal Cord Damage Identified as Potential Biomarker of Friedreich Ataxia Disease Progression
A study on patients with Friedreich ataxia showed that cervical spinal cord cross-sectional area is a potential biomarker for disease progression, particularly at C1 level.
Episode 101: Ways to Enhance Neuromodulation in Parkinsonism
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alfonso Fasano, MD, PhD. [WATCH TIME: 25 minutes]
Social Determinants of Health Lead to Greater Suboptimal Treatment Response in Myasthenia Gravis
A retrospective study presented at the 2023 AANEM meeting revealed that social determinants of health are linked to poorer treatment outcomes in myasthenia gravis patients, emphasizing the need for identifying and supporting at-risk individuals.
FDA Accepts Supurnus’ Resubmitted NDA for SPN-830 Apomorphine Infusion Device
In the phase 3 TOLEDO trial, treatment with SPN-830 resulted in significantly greater OFF time for patients with Parkinson disease in comparison with those on placebo.
Creatine Kinase Levels Not Considered Risk Factor for COVID-19 Post-Acute Sequelae
Elevated creatine kinase levels were not found to be a prognostic factor for the development of PASC in encephalopathic COVID-19 patients, according to a retrospective chart review analysis.
Decreased Neurofilament Light in ATTR Polyneuropathy Observed With Vutrisiran and Patisiran
Vutrisiran and patisiran treatment led to noticeable reductions in neurofilament light, indicating a potential biomarker of treatment response in hATTR amyloidosis patients.
Open-Label PROPEL Study Results Highlight Longterm Impact of Cipaglucosidase Alfa and Miglustat in Late-Onset Pompe Disease
The phase 3 PROPEL study demonstrated the long-term effectiveness of cipaglucosidase alfa/miglustat in late-onset Pompe disease, with improved 6-minute walk distance and lung function.
Latozinemab Shows No Impact on Disease Progression in C9orf72 Frontotemporal Dementia Despite increasing Progranulin Expression
latozinemab treatment for C9orf72-associated frontotemporal dementia showed no significant impact on disease progression, although the treatment was generally safe and well-tolerated.
NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease
David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.
SRP-9001 Fails to Meet Primary End Point in Phase 3 EMBARK Study
Over a 52-week treatment period, SRP-9001 demonstrated robust evidence for a clinically meaningful benefit across several prespecified functional secondary end points in comparison with placebo.
Clinician Specialty Shows No Impact on Migraine Preventives Rates Among Young Adults
In a sample of more than 750 patients with migraine, clinician specialty had no impact on preventive prescription, with small differences observed in the choice of tricyclic antidepressants.
2 Clarke Drive Cranbury, NJ 08512